Variability of physiologically based pharmacokinetic (PBPK) model parameters and their effects on PBPK model predictions in a risk assessment for perchloroethylene (PCE).

When used in the risk assessment process, the output from physiologically based pharmacokinetic (PBPK) models has usually been considered as an exact estimate of dose, ignoring uncertainties in the parameter values used in the model and their impact on model predictions. We have collected experimental data on the variability of key parameters in a PBPK model for tetrachloroethylene (PCE) and have used Monte Carlo analysis to estimate the resulting variability in the model predictions. Blood/air and tissue/blood partition coefficients and the interanimal variability of these data were determined for tetrachloroethylene (PCE). The mean values and variability for these and other published model parameters were incorporated into a PBPK model for PCE and a Monte Carlo analysis (n = 600) was performed to determine the effect on model predicted dose surrogates for a PCE risk assessment. For a typical dose surrogate, area under the blood time curve for metabolite in the liver (AUCLM), the coefficient of variation was 25% and the mean value for AUCLM was within a factor of two of the maximum and minimum values generated in the 600 simulations. These calculations demonstrate that parameter uncertainty is not a significant potential source of variability in the use of PBPK models in risk assessment. However, we did not in this study consider uncertainties as to metabolic pathways, mechanism of carcinogenicity, or appropriateness of dose surrogates.

[1]  B. Allen,et al.  Evaluation of uncertainty in input parameters to pharmacokinetic models and the resulting uncertainty in output. , 1989, Toxicology letters.

[2]  P. Watanabe,et al.  The pharmacokinetics and macromolecular interactions of perchloroethylene in mice and rats as related to oncogenicity. , 1980, Toxicology and applied pharmacology.

[3]  F. A. Smith,et al.  Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. , 1987, Toxicology and applied pharmacology.

[4]  D W Potter,et al.  A physiologically based pharmacokinetic and pharmacodynamic model to describe the oral dosing of rats with ethyl acrylate and its implications for risk assessment. , 1992, Toxicology and applied pharmacology.

[5]  M E Andersen,et al.  Partition coefficients of low-molecular-weight volatile chemicals in various liquids and tissues. , 1989, Toxicology and applied pharmacology.

[6]  F Y Bois,et al.  Precision and sensitivity of pharmacokinetic models for cancer risk assessment: tetrachloroethylene in mice, rats, and humans. , 1990, Toxicology and applied pharmacology.

[7]  J. Buben,et al.  Delineation of the role of metabolism in the hepatotoxicity of trichloroethylene and perchloroethylene: a dose-effect study. , 1985, Toxicology and applied pharmacology.

[8]  R. D. Stewart,et al.  Experimental human exposure to trichloroethylene. , 1970, Archives of environmental health.

[9]  P. Watanabe,et al.  Disposition of tetrachloro(14C)ethylene following oral and inhalation exposure in rats. , 1979, Toxicology and applied pharmacology.

[10]  P. S. McCroskey,et al.  Development of a physiologically based pharmacokinetic model for risk assessment with 1,4-dioxane. , 1990, Toxicology and applied pharmacology.

[11]  D. Pierson,et al.  Mechanism of transport and distribution of organic solvents in blood. , 1990, Toxicology and applied pharmacology.

[12]  D Hattis,et al.  Uncertainties in pharmacokinetic modeling for perchloroethylene. I. Comparison of model structure, parameters, and predictions for low-dose metabolism rates for models derived by different authors. , 1990, Risk analysis : an official publication of the Society for Risk Analysis.

[13]  E. Gubéran,et al.  Experimental human exposures to tetrachloroethylene vapor and elimination in breath after inhalation. , 1976, American Industrial Hygiene Association journal.